Helen Y Chen

US Patent:

6383486, May 7, 2002

Filed:

Jul 1, 1999

Appl. No.:

09/348886

Inventors:

Terri Lynn Davis-Smyth - Foster City CA
Helen Hsifei Chen - Daly City CA
Leonard Presta - San Francisco CA
Napoleone Ferrara - San Francisco CA

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

A61K 39395

US Classification:

4241581, 514 2, 530350, 530324

Abstract:

The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization.

US Patent:

6897294, May 24, 2005

Filed:

Mar 20, 2002

Appl. No.:

10/105901

Inventors:

Terri Lynn Davis-Smyth - Foster City CA, US
Helen Hsifei Chen - Daly City CA, US
Leonard Presta - San Francisco CA, US
Napoleone Ferrara - San Francisco CA, US

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

C07K014/00
C12P021/04

US Classification:

530350, 435 697

Abstract:

The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization.

US Patent:

7771721, Aug 10, 2010

Filed:

Apr 17, 2008

Appl. No.:

12/104825

Inventors:

Terri Lynn Davis-Smyth - Foster City CA, US
Helen Hsifei Chen - Daly City CA, US
Leonard Presta - San Francisco CA, US
Napoleone Ferrara - San Francisco CA, US

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

A61K 38/18
C07K 14/71
C12N 15/62

US Classification:

4241341, 4241921, 514 2, 530350, 536 234

Abstract:

The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and anglogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization.

US Patent:

8268313, Sep 18, 2012

Filed:

Apr 28, 2011

Appl. No.:

13/096742

Inventors:

Terri Lynn Davis-Smyth - Foster City CA, US
Helen Hsifei Chen - Daly City CA, US
Leonard Presta - San Francisco CA, US
Napoleone Ferrara - San Francisco CA, US

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

A61K 38/18
C07K 14/71

US Classification:

4241341, 4241921, 514 11, 514 133, 514 212, 530350

Abstract:

The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization.

US Patent:

8268591, Sep 18, 2012

Filed:

Apr 28, 2011

Appl. No.:

13/096734

Inventors:

Terri Lynn Davis-Smyth - Foster City CA, US
Helen Hsifei Chen - Daly City CA, US
Leonard Presta - San Francisco CA, US
Napoleone Ferrara - San Francisco CA, US

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

C12N 15/62
C12N 15/63
C07H 21/00

US Classification:

435 697, 4352523, 4353201, 435325, 435358, 4241921, 536 234

Abstract:

The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization.

US Patent:

8273353, Sep 25, 2012

Filed:

Apr 28, 2011

Appl. No.:

13/096723

Inventors:

Terri Lynn Davis-Smyth - Foster City CA, US
Helen Hsifei Chen - Daly City CA, US
Leonard Presta - San Francisco CA, US
Napoleone Ferrara - San Francisco CA, US

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

A61K 38/18
C07K 14/71

US Classification:

4241341, 4241921, 514 11, 514 133, 514 212, 530350

Abstract:

The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization.

US Patent:

20050281831, Dec 22, 2005

Filed:

Jan 26, 2005

Appl. No.:

11/043693

Inventors:

Terri Davis-Smyth - Foster City CA, US
Helen Chen - Daly City CA, US
Leonard Presta - San Francisco CA, US
Napoleone Ferrara - San Francisco CA, US

Assignee:

Genentech, Inc. - South San Francisco CA

International Classification:

A61K039/395
A61K038/18

US Classification:

424178100, 514012000

Abstract:

The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization.

US Patent:

20070128695, Jun 7, 2007

Filed:

Sep 30, 2006

Appl. No.:

11/537623

Inventors:

Terri Davis-Smyth - Foster City CA, US
Helen Chen - Daly City CA, US
Leonard Presta - San Francisco CA, US
Napoleone Ferrara - San Francisco CA, US

Assignee:

Genentech,Inc. - South San Francisco CA

International Classification:

C07K 14/71
C07K 16/28
C07H 21/04
C12P 21/06

US Classification:

435069100, 530350000, 435320100, 435325000, 530388220, 536023500

Abstract:

The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization.